Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Tripathy on Completing New Assays After Recurrence

August 18th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

The Great Biomarker Chase: Promise & Pitfalls Along the Path to Personalized Care

August 16th 2011

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Dr. Wolff Discusses the Importance of HER2 Testing

August 15th 2011

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Tripathy on the Oncotype DX Assay Recurrence Score

August 15th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. Tripathy Discusses Breast Cancer Gene Profiling

August 12th 2011

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Tripathy Discusses Breast Cancer Biomarkers

August 11th 2011

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

In the Pipeline

August 10th 2011

Amid a continuing emphasis on targeted therapies, pharmaceutical companies have approximately 300 drugs in phase II or later-stage development for cancer treatment.

Dr. Kris Discusses Available Targeted Therapies

August 10th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies

Industry Testing New Models for Developing Biomarkers

August 10th 2011

As personalized medicine occupies a growing role in the pharmaceutical pipeline, major companies are changing their research and development paradigms.

New Clinical Trial Designs Needed for Marker-Based Studies

August 9th 2011

The oncology community is quite conversant with the clinical utility of prognostic tumor markers.

Quality-of-Life Targeted Therapies

August 8th 2011

In the context of caring for cancer patients, all physicians and nurses trained in oncology receive education in quality-of-life issues; however, prolonging quantity of life remains our ultimate goal.

Novel Therapeutics Target Gene Mutations, Tumor Suppressors

August 2nd 2011

Previously unknown genetic methylation patterns and new mutations for squamous cell carcinoma of the head and neck discovered.

Study Finds Erlotinib Superior to Conventional Chemotherapy in Treatment of EGFR-Mutated Advanced NSCLC

August 2nd 2011

PFS improved significantly in patients with EGFR-mutated advanced NSCLC treated first line with erlotinib versus platinum-based chemotherapy.

Dr. West Discusses Anticipated Future Clinical Trials

August 1st 2011

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

Those Eureka Moments Glisten: A Conversation With Robert A. Weinberg, PhD

August 1st 2011

When Robert A. Weinberg was a boy, he loved dissecting what was complicated and figuring out what made it work.

Building Blocks of a Biotech: CytRx Executives Talk About 3 Agents for Multiple Tumors

July 29th 2011

Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.

Dr. Kris on How the Institutes in His Study Worked Together

July 28th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on How the Institutes in the mutlicenter study examining driver mutations Worked Together

MetMAb Plus Erlotinib Improves Survival for Patients With MET-Positive NSCLC

July 28th 2011

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

Dr. West on 4 Important Upcoming Clinical Trial Results

July 28th 2011

Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.

Dr. Tsimberidou on the Next Steps for Personalized Care

July 27th 2011

Dr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care